Chanise Frandsen
Physician Assistant · Sandy, UTNPI 1083211759
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 35.3% of the total. 2025 is the largest year on record at $16,958, 8.7 times the $1,941 reported in 2021. Among physician assistant clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 526 payments — averaging $59.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$11K
- AstraZeneca$6K
- Blueprint Medicines Corporation$5K
- Sanofi$2K
- GSK$2K
- Novartis$565
- plus $5K from 37 others
What the payments were for
- Consulting fees$190%
- Speaking & faculty fees$14,04045%
- Travel & lodging$2,6468%
- Food & beverage$14,47346%
- Education$1801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,358 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $38,297 |
| Spiriva RespimatTiotropium Bromide | 14 | $14,520 |
| DuleraMometasone/Formoterol | 28 | $10,695 |
| Cromolyn Sodium | 15 | $10,303 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $9,366 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $8,929 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $7,146 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $6,463 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $5,731 |
| Mometasone Furoate | 12 | $1,342 |
| Theo-24Theophylline Anhydrous | 12 | $1,245 |
| Montelukast Sodium | 111 | $1,203 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,070 |
| Levocetirizine Dihydrochloride | 23 | $405 |
| Fluticasone Propionate | 14 | $360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,681 | $47,66359 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $324 | $23,44929 claims |
| AstraZenecaSymbicort | $5,878 | $5,73112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.
Other physician assistant in Sandy
- John WhiteheadSandy$23K
- Regan BrooksSlc$606K
- Keri HolyoakMidvale$438K
- Jill EricksonSalt Lake City$179K
- Vanessa Beard-ElyMurray$80K
- Natalie BeeSalt Lake City$63K
- Jasmin CharlesTaylorsville$46K
- Luke JenkinsWest Jordan$46K
- Alexandra RoccoWashington Terrace$31K
- Jenna RhotonOgden$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.